Search - tctmd.com

Displaying 521 - 540 of 569

Sort: Relevancy | Date

News Daily News

Anemia Inhibits Platelet Response to Clopidogrel in PCI Patients

March 21, 2012

News Daily News

Universal Definition of MI Shifts Advantage Toward Cangrelor in PCI

Caitlin E. Cox

March 20, 2012

News Daily News

La Definición Universal de IM se Posiciona en Favor del Cangrelor en las PCI

Caitlin E. Cox

March 20, 2012

News Daily News

PLATO Analysis: PPIs Problematic with Both Ticagrelor, Clopidogrel

Caitlin E. Cox

March 06, 2012

News Daily News

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

Caitlin E. Cox

March 06, 2012

News Daily News

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

Caitlin E. Cox

March 06, 2012

News Daily News

Análisis PLATO: Los IBP son Problemáticos tanto con el Ticagrelor como con el Clopidogrel

Caitlin E. Cox

March 06, 2012

News Daily News

BRIDGE Published: Cangrelor Promising Option as Bridging Therapy

January 16, 2012

News Daily News

Silent Cerebral Infarcts After Angiography Linked to Insufficient Platelet Inhibition

L.A. McKeown

January 12, 2012

News Daily News

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

December 04, 2011

News Conference News

ACCEL-BLEED: Mild Bleeding Correlated with Platelet Reactivity One Month Post PCI

November 22, 2011

News Conference News

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

November 21, 2011

News Conference News

Higher Dosing Improves Clopidogrel Response in Carriers of Variant Genes

November 16, 2011

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Conference News

BRIDGE: Cangrelor Provides Effective Maintenance of Platelet Inhibition Without Major Bleeding

November 09, 2011

News Conference News

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

November 09, 2011

News Industry News

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

November 08, 2011

News Industry News

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

November 08, 2011

Advertisement

Anemia Inhibits Platelet Response to Clopidogrel in PCI Patients

Universal Definition of MI Shifts Advantage Toward Cangrelor in PCI

La Definición Universal de IM se Posiciona en Favor del Cangrelor en las PCI

PLATO Analysis: PPIs Problematic with Both Ticagrelor, Clopidogrel

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

Análisis PLATO: Los IBP son Problemáticos tanto con el Ticagrelor como con el Clopidogrel

BRIDGE Published: Cangrelor Promising Option as Bridging Therapy

Silent Cerebral Infarcts After Angiography Linked to Insufficient Platelet Inhibition

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

ACCEL-BLEED: Mild Bleeding Correlated with Platelet Reactivity One Month Post PCI

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

Higher Dosing Improves Clopidogrel Response in Carriers of Variant Genes

Low CV Event Rate Prompts Closure of Prasugrel Trial

BRIDGE: Cangrelor Provides Effective Maintenance of Platelet Inhibition Without Major Bleeding

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content